Novo Nordisk raises 2026 outlook as Wegovy pill sales strengthen

Novo Nordisk reported third-quarter revenue and earnings above market expectations on November 4 and raised its full-year 2026 outlook. Growing sales of its Wegovy weight-loss pill were a key driver.^[1]

The Danish drugmaker launched the pill this year and is continuing its rollout. Its improved outlook covers key obesity and diabetes drugs, particularly in markets outside the United States.^[2][3]

Stronger demand for the Wegovy pill turns into revenue through additional drug sales, helping Novo offset weakness in its diabetes business. That provides a stronger commercial demand signal for companies developing oral weight-loss treatments.^[1]

Pricing pressure remains a constraint: when revenue per prescription falls, drugmakers need more sales volume to generate the same revenue. For investors, the key is whether pill growth can continue to offset lower prices and weakness elsewhere in the business.^[1]

Impact

• Weight-loss drug developers and manufacturersOpportunity

  Novo's sales performance gives rivals stronger evidence of demand when assessing oral weight-loss drug programs. Their ability to benefit still depends on their own development and sales results, while pricing pressure means higher volumes may produce smaller revenue gains.^[1]